Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Share-based Compensation (2016 - 2021)

Historic Share-based Compensation for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to $35.6 million.

  • Neurocrine Biosciences' Share-based Compensation rose 6952.38% to $35.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was $134.2 million, marking a year-over-year increase of 3420.0%. This contributed to the annual value of $195.5 million for FY2024, which is 61.76% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Share-based Compensation of $35.6 million as of Q4 2021, which was up 6952.38% from $37.1 million recorded in Q3 2021.
  • Over the past 5 years, Neurocrine Biosciences' Share-based Compensation peaked at $37.1 million during Q3 2021, and registered a low of $9.0 million during Q1 2017.
  • Moreover, its 5-year median value for Share-based Compensation was $20.1 million (2018), whereas its average is $20.5 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Share-based Compensation surged by 12146.84% in 2018, and later tumbled by 2051.91% in 2019.
  • Neurocrine Biosciences' Share-based Compensation (Quarter) stood at $13.5 million in 2017, then decreased by 1.13% to $13.3 million in 2018, then soared by 60.15% to $21.3 million in 2019, then dropped by 1.41% to $21.0 million in 2020, then skyrocketed by 69.52% to $35.6 million in 2021.
  • Its Share-based Compensation was $35.6 million in Q4 2021, compared to $37.1 million in Q3 2021 and $28.6 million in Q2 2021.